Please assess the completion status of the following clinical trial:

Trial Title: Study to Assess the Efficacy and Safety of LX201 for Prevention of Corneal Allograft Rejection Episodes and Graft Failure in Subjects at Increased Immunological Risk

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects are candidates for a corneal transplant and are at increased immunological risk for graft failure, as evidenced by one or more of the following:~  * ≥ 1 quadrant deep corneal vascularization~ * verifiable history of graft failure due to rejection~ * position of graft is \< 1 mm from the limbus~Exclusion Criteria:~* Any condition that would greatly increase the risk of non-rejection graft failure such as Stevens-Johnson syndrome, xerophthalmia or severe exposure keratitis.~* Schirmer's test ≤ 5 mm in 1 minute~* Clinical evidence of limbal stem cell deficiency~* History of or active herpes simplex virus keratitis or other acute corneal infection~* Subjects who have had \> 3 failed grafts in the study eye~* Uncontrolled glaucoma as evidenced by an intraocular pressure of \>21 mmHg while on maximal medical therapy~* Clinically suspected or confirmed ocular lymphoma~* Treatment with a systemic immunosuppressive regimen within the previous 30 days; systemic prednisone (or its equivalent) of ≤ 10 mg daily is, however, permitted.~* Any implantable corticosteroid-eluting device (e.g., Retisert™, Posurdex®, Medidur™, I-vation™ TA intravitreal implant)~* Subjects who periodically require high-dose systemic steroid treatment (e.g., for exacerbation of chronic obstructive pulmonary disease).~* Subjects who have received treatment with a monoclonal antibody or any other biologic therapy within the previous 90 days or alemtuzumab within the previous 12 months~* History of herpes zoster or varicella infection within 6 weeks prior to enrollment, or chicken pox exposure within 21 days before enrollment~* Seropositivity for human immunodeficiency virus (HIV)~* Previous exposure or known contraindication to administration of cyclosporine~* Recipients of a solid organ transplant~* Currently pregnant or lactating~* Active, extraocular and/or systemic infection requiring the prolonged or chronic use of antimicrobial agents or the presence of active hepatitis A, B or C~* Severe anemia (hemoglobin \< 6 g/dL), leukopenia (white blood cell count \[WBC\] \< 2500 mm3), thrombocytopenia (platelet count \< 80,000 mm3), polycythemia (hematocrit \[Hct\] \> 54% \[male\] or Hct \> 49% \[female\]) or clinically significant coagulopathy~* Current malignancy or a history of malignancy (within the previous 5 years) except non-metastatic basal or squamous cell carcinoma of the skin or carcinoma-in-situ of the cervix that has been treated successfully~* Active peptic ulcer disease~* Co-morbid conditions that require immunosuppression

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LX201 0.50 inch implant (Type: EXPERIMENTAL): LX201 implant contained 30% cyclosporine A by weight and 0.50 inch in length
- LX201 0.75 inch implant (Type: EXPERIMENTAL): LX201 implant contained 30% cyclosporine A by weight and 0.75 inch by length
- Placebo 0.75 inch implant (Type: PLACEBO_COMPARATOR): Silicone implant not containing cyclosporine A, 0.75 inch in length

Based on this trial design, predict the completion outcome and termination type (if applicable).